Pharma Focus Asia

Boehringer Ingelheim Begins US$99 million New Tablet Production Facility


Boehringer Ingelheim had begun construction of a new production facility for innovative drugs with an investment of US$99 million.


The new production facility will focus on the development activities for drugs in tablet form and manufacture them across the globe.

The facility will be capable for modern and flexible production and also helps to market new, innovative drugs.

It will be started in 2020 and 75 employees will develop new production methods for tablet preparations.

The new tablet production facility will continue to manufacture drugs that require highly complex production technologies.

The production facility is expected to operational by 2022.


NameBoehringer Ingelheim
BudgetUS$99 Million
ScheduleTo be operational by 2022
magazine-slider-imageHexagon - Expert Insights WebinarMFA + MMA 20244th Annual Cleaning Validation 20242nd Annual Pharma Impurity Conclave 2024CPHI Korea 2024CHEMICAL INDONESIA 2024World Orphan Drug Congress Europe 2024INALAB 2024Thermo Fisher - Drug Discovery and the impact of mAbsAdvanced Therapies USA 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference